Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

References for Chemotherapy for Tumors in the Nervous System of Children

This page was last updated on June 28th, 2022

  1. Allen JC: A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. Cancer 74: 940–944, 1994
  2. Sands SA, Oberg JA, Gardner SL, et al: Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors. Pediatr Blood Cancer 54:429-436, 2010
  3. Ater JL, Zhou T, Holmes E, et al: Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group . J Clin Oncol 30:2641–2647, 2012
  4. Bartels U, Laperriere N, Bouffet E, et al: Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne) 27:39, 2012
  5. Bouffet E, Jakacki R, Goldman S, et al: Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358-1363, 2012
  6. Cavalheiro S, Dastoli PA, Silva NS, et al: Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst 21:719-724, 2005
  7. Chi SN, Gardner SL, Levy AS, et al: Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 22:4881-4887, 2004
  8. Chintagumpala M, Hassall T, Palmer S, et al: A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 11:33-40, 2008
  9. Cohen BH, Packer RJ, Siegel KR, et al: Brain tumors in children under 2 years: treatment, survival and long-term prognosis. Pediatr Neurosurg 19:171-179, 1993
  10. Dean RL, Emerich DF, Hasler BP, et al: Cereport® (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro Oncol 1: 268-274, 1999
  11. Dhall G, Grodman H, Ji L, et al: Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 50:1169-75, 2008
  12. Dunkel IJ, Finlay JL: High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit Rev Oncol Hematol 41:197-204, review, 2002
  13. Ertel I, Boesal C : Adjuvant chemotherapy of high grade astrocytomas in children: Radiation therapy with or without CCNU, vincristine, and prednisone. Pediatr Neurosci 12:272-282, 1985-1986
  14. Evans AE, Jenkin RD, Sposto R, et al: The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572-582, 1990
  15. Fangusaro J, Finlay J, Sposto R, et al: Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 50:312-318, 2008
  16. Finlay JL, Dhall G, Boyett JM, et al: Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer 51:806-811, 2008
  17. Garvin JH, Selch MT, Holmes E, et al: Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: A report from the Children’s Oncology Group. Pediatr Blood Cancer 59:1183-1189, 2012
  18. Geyer JR, Finlay JL, Boyett JM, et al: Survival of infants with malignant astrocytomas. A report from the Children’s Cancer Group. Cancer 75:1045-1050, 1995
  19. Grundy RG, Wilne SA, Weston CL, et al: Primary post-operative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8:696-705, 2007
  20. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
  21. Hukin J, Siffert J, Velasquez L, et al: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol 4:253-260, 2002
  22. Steinbok P, Hukin J: Intracystic treatments for craniopharyngioma. Neurosurg Focus 28 (4): E13, 2010
  23. Hukin J, Steinbok P, Lafay-Cousin L, et al: Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 109:2124-2131, 2007
  24. Stewart CF, Iacono LC, Chintagumpala M, et al: Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22:3357-3365, 2004
  25. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 16:210-221, 1998
  26. Needle MN, Goldwein JW, Grass J, et al: Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 80:341-347, 1997
  27. Rutkowski S, Bode U, Deinlein F, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978-986, 2005
  28. Krueger DA, Care MM, Holland K, et al: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811, 2010
  29. Jakacki RI, Burger PC, Zhou T, et al: Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study. J Clin Oncol 30:2648-2653, 2012
  30. Lafay-Cousin L, Hawkins C, Carret AS, et al: Central nervous system atypical teratoid rhabdoid tumors: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 48:353-359, 2012
  31. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
  32. Liu AK, Macy ME, Foreman NK, et al: Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiation Oncology Biol Phys 75:1148–1154, 2009
  33. Linnebank M, Moskau S, Jurgens A, et al: Association of genetics variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 11:2-8, 2009
  34. Northcott PA, Dubuc AM, Pfister S, et al: Molecular subgroups of medulloblastoma. Expert Rev Neurother 12:871-884, 2012
  35. Packer RJ, Ater J, Allen J, et al: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. Neurosurgery 86:747-754, 1997
  36. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 17:2127-2136, 1999
  37. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202-4208, 2006
  38. Pollack IF, Hamilton RL, Sobol RW, et al: O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431-3437, 2006
  39. Ross CJ, Katzov-Eckert H, Dubé MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345-1349, 2009
  40. Sasazaki Y, Asami K, Utsumi J: Transient subacute encephalopathy induced by high-dose methotrexate treatment in children with acute lymphoblastic leukemia and malignant lymphoma. Gan To Kagaku Ryoho 19:1851-1857, 1992
  41. Strother D, Ashley D, Kellie SJ, et al: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 19: 2696-2704, 2001
  42. Strunk T, Gottschalk S, Goepel W, et al: Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Med Pediatr Oncol 40:48-50, 2003
  43. Van den Bent MJ: Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. Clin Cancer Res 11:1691-693, 2005
  44. Zacharoulis S, Levy A, Chi SN, et al: Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49:34-40, 2007
  45. Miesea F.R, Schusterb FR, Pierstorff K, et al: Magnetization transfer imaging provides no evidence of demyelination in methotrexate-induced encephalopathy. Am J Neuroradiol 32:E110 –E112, 2011
  46. Chi SN, Zimmerman MA, Yao X, et al: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385-389, 2009
  47. Pollack IF, Jakacki RI, Butterfield LH, et al: Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Philadelphia (PA): AACR. 2012, (Abstract LB131).
  48. Triscott J, Lee C, Foster C, et al: Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 73; 6734–6744, 2013
  49. Galanis E, Jaeckle KA, Maurer MJ, et al: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 27: 2052-2058, 2009
  50. Li MH, Bouffet E, Hawkins CE, et al: Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg Focus 19 (5):E3, 2005
  51. Guidelines for platelet thresholds for pediatric hematology/oncology patients: Complete reference guide. Edmonton, CA: The C17 Guidelines Committee, 2011 (http://www.c17.ca/index.php/download_file/view/41/) [Accessed 25 January 2014]
  52. Comparison of radiation therapy regimens in combination with chemotherapy in treating young patients with newly diagnosed standard-risk medulloblastoma. Bethesda, MD: Children’s Oncology Group/National Cancer Institute, 2013 (http://www.cancer.gov/clinicaltrials/search/view?cdrid=365506&version=HealthProfessional) [Accessed 25 January 2014]
  53. Edwards M, Levin V, Wilson C: Brain tumor chemotherapy:An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64:1179-1205, 1980.
  54. Duffner PK, Horowitz ME, Krischer JP et al: The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience. Neurooncology April 1(2):152-161, 1999. 
  55. Massimino M, Spreafico F, Cefalo G et al : High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. Journal of Clinical Oncology, Vol 20, No 20 (October 15), 2002: pp 4209-4216
  56. Packer RJ, Jakacki R, Horn M et al: Objective Response of Multiply Recurrent Low-Grade Gliomas to Bevacizumab and Irinotecan. Pediatr Blood Cancer 2009;52:791–795
  57. Balmaceda C Heller G, Rosenblum M, et al:  Chemotherapy without irradiation–a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study.  J Clin Oncol 14:2908-2915, 1996
  58. Roberge D, Kun LE, Freeman CR: Intracranial germinoma: On whole ventricular irradiation. Pediatr Blood Cancer 44:358 –362, 2005
  59. Matsutani M; Japanese Pediatric Brain Tumor Study Group: Combined
    chemotherapy and radiation therapy for CNS germ cell tumors – the Japanese experience. J Neurooncol 2001;54:311–316, 2001
  60. Kellie SJ, Boyce H, Dunkel IJ, et al:  Primary chemotherapy for intracranial nongerminomatous germ cell tumors: Results of the Second International CNS Germ Cell Study Group Protocol.  J Clin Oncol 22:846-853,  2004
  61. Glass T, Cochrane DD, Rassekh SR, et al:  Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): a risk for secondary malignant transformation – a report of two cases.  Childs Nerv Syst Oct 12, 2013 (epub ahead of print)
  62. Kim JW, Kim WC, Cho JH, et al:  A multimodal approach including craniospinal irradiation improves the treatment outcome of high-risk intracranial nongerminomatous germ cell tumors.  Int J Radiat Oncol Biol Phys 84:625-631, 2012.
  63. Calaminus G, Kortmann R, Worch J, et al:  SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease.  Neuro Oncol 15:788-796, 2013.
  64. Robertson PL, Jakacki R,  Hukin J, et al:  Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study.  J Neurooncol, published online 4 April, 2014

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.